CVS Health Corp director Guy P. Sansone received a stock grant as part of his board compensation. He acquired 1,447 shares of common stock valued at $97.15 per share, issued in payment of a semi-annual retainer at the market price under the 2017 Incentive Compensation Plan. Following this grant, he directly holds 15,106.355 CVS shares.
CVS Health director Alecia A. Decoudreaux received a compensation-related grant of deferred stock units. On May 14, 2026, she was awarded 1,447.5039 deferred stock units valued at $97.15 per unit for deferring a semi-annual director retainer under CVS Health’s 2017 Incentive Compensation Plan. Each unit will later convert into one share of common stock, to be issued in the future according to her election. Following this grant, she directly holds a total of 42,181.8314 deferred stock units. The filing shows no open-market purchases or sales, only this grant/award acquisition.
CVS Health Corp director Anne A. Finucane reported receiving a grant of 1,544.0041 Deferred Stock Units as compensation. These units represent the deferral of a semi-annual director retainer, valued at a reference price of $97.15 per unit under CVS’s 2017 Incentive Compensation Plan.
Each deferred stock unit is designed to convert into one share of CVS common stock and be issued in the future, based on the director’s election. Following this award, Finucane holds a total of 18,355.0364 deferred stock units, reflecting her accumulated deferred board compensation.
BROWN C DAVID II reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director C. David Brown II received 1,544 shares of Common Stock as compensation. The shares were issued at a reference price of $97.15 per share as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, rather than bought on the open market.
After this grant, Brown directly holds 129,316 CVS shares. This is a routine equity award tied to board service and not an open-market purchase or sale.
CVS Health director Douglas H. Shulman received a grant of 1,447.5039 deferred stock units as compensation. The award represents deferral of a semi-annual director retainer under CVS Health’s 2017 Incentive Compensation Plan and is valued at $97.15 per unit. Each deferred stock unit is scheduled to convert into one share of CVS common stock and be issued in the future, according to the timing Mr. Shulman has elected. This is a compensation-related, non‑market transaction rather than an open‑market purchase or sale.
CVS Health Corp director Larry Robbins reported an acquisition of deferred stock units as part of non-employee director compensation. He received 1,930.0051 deferred stock units valued at $97.15 per unit, bringing his direct holdings of deferred stock units to 10,147.6418.
The award reflects a deferral of a semi-annual retainer under CVS Health’s 2017 Incentive Compensation Plan. Each deferred stock unit is designed to convert into one share of common stock, issuable when Robbins retires from the CVS Health Board of Directors, consistent with his deferral election.
CVS Health executive vice president and Chief Experience & Technology Officer Tilak Mandadi sold 69,551 shares of CVS common stock in an open-market transaction. The shares were sold at an average price of about $89.58 per share, with prices ranging between $89.30 and $89.81. After this sale, Mandadi directly holds 10,133 CVS shares.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting proposed sales of Common stock tied to restricted stock awards with multiple grant dates. The notice lists proposed quantities by grant date, including 20,229 and 20,449 share lots and additional smaller tranches, with transaction venue noted as NYSE.
CVS Health Corp filed a Form 13F reporting its institutional holdings. The filing lists 33 Form 13F information table entries with a total reported market value of $212,255,190. The report is signed by Michael Motolo and dated 05-07-2026.
CVS Health Corporation reported higher quarterly earnings on modest revenue growth. For the three months ended March 31, 2026, total revenues rose to $100.4 billion from $94.6 billion a year earlier, driven mainly by growth in pharmacy products and premiums across its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.
Net income attributable to CVS Health increased to $2.94 billion from $1.78 billion, with diluted earnings per share rising to $2.30 from $1.41. Operating income improved to $4.68 billion, reflecting higher operating margins and fewer large one‑time charges than in the prior year.
Cash and cash equivalents were $9.54 billion as of March 31, 2026, up from $8.45 billion at year-end 2025, while net cash provided by operating activities was $4.25 billion. Long-term debt remained sizable at about $60.5 billion, but total shareholders’ equity increased to $77.6 billion, supported by retained earnings growth and consistent quarterly dividends of $0.665 per share.